Overview: Why Thrombotic Risk Matters in HR+/HER2- Breast Cancer Venous thromboembolism (VTE) is a well-recognized complication in cancer patients, including those with hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. While targeted endocrine therapies and CDK4/6 inhibitors have improved outcomes, they may also influence thrombosis risk through complex interactions with tumor biology, treatment regimens, and…